GlassScriptPhysician profile
Arielle Rounds
NPI 1396372280
$14,541.75
in general payments reported to CMS, 2019-2025
22 companies · $3,543 in 2025
The $3,543 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,751 · 2022: $3,223 · 2023: $2,818 · 2024: $3,208 · 2025: $3,543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,555 · Education: $13.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,554.74 |
| Education | $13.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,821.90 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,420.09 | 2021-2025 | Rexulti, Abilify Mycite, Nuedexta |
| Vanda Pharmaceuticals INC. | $1,416.18 | 2021-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,256.87 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $1,194.56 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $1,057.88 | 2022-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $938.93 | 2021-2025 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $664.78 | 2022-2025 | Ingrezza |
| Corium, LLC | $558.30 | 2022-2025 | Azstarys |
| Lundbeck LLC | $396.23 | 2021-2025 | Rexulti |
| Collegium Pharmaceutical, INC. | $323.24 | 2025 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $288.19 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Tris Pharma INC | $241.98 | 2022-2025 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $214.27 | 2021-2025 | Spravato |
| Supernus Pharmaceuticals, INC. | $201.96 | 2022-2025 | Qelbree, Qelbree |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $191.48 | 2021 | |
| Bausch Health US, LLC | $103.58 | 2022-2024 | Aplenzin, Wellbutrin |
| Neos Therapeutics, LP | $96.67 | 2021-2024 | Adzenys Xr-Odt |
| Idorsia Pharmaceuticals US INC | $54.87 | 2023 | Quviviq |
| Eisai INC. | $46.33 | 2021-2022 | |
| Almatica Pharma LLC | $32.13 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.33 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arielle Rounds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.